Contact
searchSearch
HMP Global

Biosimilars Topic Center

News
Biosimilars Gain Market Traction but Adoption Varies by Demographics and Other Factors
03/18/2025
Biosimilars are gaining market share and reducing drug costs, but patient adoption varies based on demographics, care settings, and payer policies.
Biosimilars are gaining market share and reducing drug costs, but patient adoption varies based on demographics, care settings, and payer policies.
Biosimilars are gaining market...
03/18/2025
First Report Managed Care
News
Unlocking Cost-Efficiency and Access With Biosimilar Bevacizumab in Medicare
03/13/2025
New research shows significant cost savings and potential for expanded access to biosimilar bevacizumab in Medicare for patients with metastatic colorectal and non-small cell lung cancer.
New research shows significant cost savings and potential for expanded access to biosimilar bevacizumab in Medicare for patients with metastatic colorectal and non-small cell lung cancer.
New research shows significant...
03/13/2025
First Report Managed Care
News
Shifting Trends in Trastuzumab Utilization As Biosimilar Adoption Increases
03/05/2025
The use of trastuzumab for treating breast and other cancers has declined as trastuzumab biosimilars gain widespread adoption in the US.
The use of trastuzumab for treating breast and other cancers has declined as trastuzumab biosimilars gain widespread adoption in the US.
The use of trastuzumab for...
03/05/2025
First Report Managed Care
News
Biosimilar Adalimumab Adoption Could Yield Millions in Cost Savings, Study Finds
02/20/2025
A financial analysis reveals that adopting biosimilar adalimumab in commercial health plans could lead to substantial cost savings with minimal medical cost implications.
A financial analysis reveals that adopting biosimilar adalimumab in commercial health plans could lead to substantial cost savings with minimal medical cost implications.
A financial analysis reveals...
02/20/2025
First Report Managed Care
News
IQVIA Report Highlights Growing ‘Biosimilar Void’ as Biologic Patent Expiries Accelerate
02/13/2025
A new report by the IQVIA Institute warns that a growing "biosimilar void" could cost the US health care system billions in missed savings as biologic patent expirations accelerate over the next decade.
A new report by the IQVIA Institute warns that a growing "biosimilar void" could cost the US health care system billions in missed savings as biologic patent expirations accelerate over the next decade.
A new report by the IQVIA...
02/13/2025
First Report Managed Care
News
Differences in Post-Induction Levels and Response Rates Between Crohn's Disease and Ulcerative Colitis Medications
02/06/2025
A comparison of infliximab brands Inflectra and Remsima in patients with Crohn's disease and ulcerative colitis reveals differences in post-induction levels and response rates, suggesting potential considerations for dosing adjustments based...
A comparison of infliximab brands Inflectra and Remsima in patients with Crohn's disease and ulcerative colitis reveals differences in post-induction levels and response rates, suggesting potential considerations for dosing adjustments based...
A comparison of infliximab...
02/06/2025
First Report Managed Care
News
Biosimilar Competition Reduces Adalimumab Spending but Faces Challenges in Uptake
01/20/2025
In the first year of biosimilar competition for adalimumab, spending on the drug decreased by nearly 50%, yet biosimilars accounted for less than 2% of prescriptions in the US.
In the first year of biosimilar competition for adalimumab, spending on the drug decreased by nearly 50%, yet biosimilars accounted for less than 2% of prescriptions in the US.
In the first year of biosimilar...
01/20/2025
First Report Managed Care
News
Biosimilars Expand Access and Cut Costs in HER2-Positive Cancer Treatment
01/10/2025
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
Biosimilar versions of trastuzumab have rapidly gained market share in treating HER2-positive breast cancer since their introduction to the US markets.
Biosimilar versions of...
01/10/2025
First Report Managed Care
News
Provider Perceptions of Biosimilar Use in Oncology Networks
01/03/2025
Research published in the Journal of the American Pharmacists Association examined provider perceptions of barriers to biosimilar use in a large oncology network, revealing low levels of perceived barriers and high utilization rates, with...
Research published in the Journal of the American Pharmacists Association examined provider perceptions of barriers to biosimilar use in a large oncology network, revealing low levels of perceived barriers and high utilization rates, with...
Research published in the...
01/03/2025
First Report Managed Care
Kolodziej Headshot
Videos
Navigating Biosimilar Adoption: Lessons from Global Markets and Clinical Practices
12/20/2024
In this interview, Michael Kolodziej, MD, discusses strategies for enhancing biosimilar adoption in the US, emphasizing lessons from global markets, the importance of payer flexibility, and the need for collaboration to reduce costs and...
In this interview, Michael Kolodziej, MD, discusses strategies for enhancing biosimilar adoption in the US, emphasizing lessons from global markets, the importance of payer flexibility, and the need for collaboration to reduce costs and...
In this interview, Michael...
12/20/2024
First Report Managed Care
Industry Insights
News Conference Coverage
Expert Perspectives
Videos Podcasts
Issue Content
Managed Care Q&A

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use